| Convergent antibody responses to SARS-CoV-2 in convalescent individuals DF Robbiani, C Gaebler, F Muecksch, JCC Lorenzi, Z Wang, A Cho, ... Nature 584 (7821), 437-442, 2020 | 1952 | 2020 |
| Evolution of antibody immunity to SARS-CoV-2 C Gaebler, Z Wang, JCC Lorenzi, F Muecksch, S Finkin, M Tokuyama, ... Nature 591 (7851), 639-644, 2021 | 1642 | 2021 |
| mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants Z Wang, F Schmidt, Y Weisblum, F Muecksch, CO Barnes, S Finkin, ... Nature 592 (7855), 616-622, 2021 | 1449 | 2021 |
| Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies CO Barnes, AP West, KE Huey-Tubman, MAG Hoffmann, NG Sharaf, ... Cell 182 (4), 828-842. e16, 2020 | 753 | 2020 |
| Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection Z Wang, F Muecksch, D Schaefer-Babajew, S Finkin, C Viant, C Gaebler, ... Nature 595 (7867), 426-431, 2021 | 712 | 2021 |
| Combination therapy with anti-HIV-1 antibodies maintains viral suppression P Mendoza, H Gruell, L Nogueira, JA Pai, AL Butler, K Millard, ... Nature 561 (7724), 479-484, 2018 | 457 | 2018 |
| Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination A Cho, F Muecksch, D Schaefer-Babajew, Z Wang, S Finkin, C Gaebler, ... Nature 600 (7889), 517-522, 2021 | 257 | 2021 |
| Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations F Muecksch, Y Weisblum, CO Barnes, F Schmidt, D Schaefer-Babajew, ... Immunity 54 (8), 1853-1868. e7, 2021 | 237 | 2021 |
| Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals Y Bar-On, H Gruell, T Schoofs, JA Pai, L Nogueira, AL Butler, K Millard, ... Nature medicine 24 (11), 1701-1707, 2018 | 225 | 2018 |
| Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost F Muecksch, Z Wang, A Cho, C Gaebler, T Ben Tanfous, J DaSilva, ... Nature 607 (7917), 128-134, 2022 | 197 | 2022 |
| Relationship between latent and rebound viruses in a clinical trial of anti–HIV-1 antibody 3BNC117 YZ Cohen, JCC Lorenzi, L Krassnig, JP Barton, L Burke, J Pai, CL Lu, ... Journal of Experimental Medicine 215 (9), 2311-2324, 2018 | 100 | 2018 |
| Prolonged viral suppression with anti-HIV-1 antibody therapy C Gaebler, L Nogueira, E Stoffel, TY Oliveira, G Breton, KG Millard, ... Nature 606 (7913), 368-374, 2022 | 78 | 2022 |
| Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: a randomized, phase 1 study YZ Cohen, AL Butler, K Millard, M Witmer-Pack, R Levin, C Unson-O’Brien, ... PLoS One 14 (8), e0219142, 2019 | 65 | 2019 |
| Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination D Schaefer-Babajew, Z Wang, F Muecksch, A Cho, M Loewe, M Cipolla, ... Nature 613 (7945), 735-742, 2023 | 43 | 2023 |
| Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection in humans Z Wang, P Zhou, F Muecksch, A Cho, T Ben Tanfous, M Canis, L Witte, ... Journal of Experimental Medicine 219 (12), e20221006, 2022 | 42 | 2022 |
| Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies F Muecksch, Y Weisblum, CO Barnes, F Schmidt, D Schaefer-Babajew, ... BioRxiv, 2021 | 41 | 2021 |
| Neutralizing activity of broadly neutralizing anti-HIV-1 antibodies against clade B clinical isolates produced in peripheral blood mononuclear cells YZ Cohen, JCC Lorenzi, MS Seaman, L Nogueira, T Schoofs, L Krassnig, ... Journal of virology 92 (5), 10.1128/jvi. 01883-17, 2018 | 41 | 2018 |
| Increased potency and breadth of SARS-CoV-2 neutralizing antibodies after a third mRNA vaccine dose F Muecksch, Z Wang, A Cho, C Gaebler, TB Tanfous, J DaSilva, ... BioRxiv, 2022.02. 14.480394, 2022 | 38 | 2022 |
| Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial H Gruell, JD Gunst, YZ Cohen, MH Pahus, JJ Malin, M Platten, KG Millard, ... The Lancet Microbe 3 (3), e203-e214, 2022 | 33 | 2022 |
| Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens Z Wang, F Muecksch, F Muenn, A Cho, S Zong, R Raspe, V Ramos, ... Journal of Experimental Medicine 219 (10), e20220826, 2022 | 18 | 2022 |
